Alembic Pharmaceuticals Limited · NSE: APLLTD · BSE: 533573
Alembic Pharmaceuticals
Quarterly results as filed with BSE. Latest: Q1 FY27 (Apr–Jun 2026), filed 04 Aug 2026.
Q1 FY27 · Consolidated
Revenue
2,149.77₹ Cr
+25.7% vs year ago
Net profit
172.36₹ Cr
+12.2% vs year ago
EPS, basic
8.80₹
+12.1% vs year ago
Net margin
8.0%
−1.0 pts vs year ago
Quarter by quarter
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 2,149.77 | +25.7% | 172.36 | +12.2% | 8.80 | 04 Aug 2026 |
| Q4 FY26Jan–Mar 2026 | 1,847.72 | +4.4% | 201.54 | +28.7% | 10.31 | 13 Jul 2026 |
| Q3 FY26Oct–Dec 2025 | 1,876.31 | +10.8% | 131.95 | −4.2% | 6.76 | 05 Feb 2026 |
| Q2 FY26Jul–Sep 2025 | 1,910.15 | +15.9% | 183.71 | +20.0% | 9.40 | 04 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 1,710.72 | +9.5% | 153.63 | +14.2% | 7.85 | 05 Aug 2025 |
| Q4 FY25Jan–Mar 2025 | 1,769.64 | +16.7% | 156.63 | −12.1% | 7.98 | 06 May 2025 |
| Q3 FY25Oct–Dec 2024 | 1,692.74 | +3.8% | 137.69 | −23.7% | 7.00 | 03 Feb 2025 |
| Q2 FY25Jul–Sep 2024 | 1,647.98 | +3.3% | 153.15 | +12.1% | 7.79 | 07 Nov 2024 |
| Q1 FY25Apr–Jun 2024 | 1,561.73 | +5.1% | 134.54 | +11.6% | 6.84 | 14 Aug 2024 |
| Q4 FY24Jan–Mar 2024 | 1,516.98 | +7.9% | 178.21 | +16.8% | 9.07 | 10 May 2024 |
| Q3 FY24Oct–Dec 2023 | 1,630.57 | +8.1% | 180.46 | +48.0% | 9.18 | 06 Feb 2024 |
| Q2 FY24Jul–Sep 2023 | 1,594.93 | +8.1% | 136.56 | +2.4% | 6.95 | 09 Nov 2023 |
| Q1 FY24Apr–Jun 2023 | 1,486.15 | +17.7% | 120.60 | Turned profit | 6.13 | 04 Aug 2023 |
| Q4 FY23Jan–Mar 2023 | 1,406.45 | −0.7% | 152.60 | +402.2% | 7.76 | 06 May 2023 |
| Q3 FY23Oct–Dec 2022 | 1,509.02 | +18.7% | 121.92 | −27.6% | 6.20 | 02 Feb 2023 |
| Q2 FY23Jul–Sep 2022 | 1,475.01 | +14.1% | 133.35 | −18.7% | 6.78 | 11 Nov 2022 |
| Q1 FY23Apr–Jun 2022 | 1,262.14 | −4.8% | (65.90) | Turned loss | (3.35) | 05 Aug 2022 |
| Q4 FY22Jan–Mar 2022 | 1,415.74 | +10.6% | 30.39 | −87.5% | 1.80 | 04 May 2022 |
| Q3 FY22Oct–Dec 2021 | 1,271.70 | −3.2% | 168.29 | −41.1% | 8.97 | 10 Feb 2022 |
| Q2 FY22Jul–Sep 2021 | 1,292.32 | −11.3% | 163.99 | −49.6% | 8.61 | 11 Nov 2021 |
| Q1 FY22Apr–Jun 2021 | 1,326.03 | −1.1% | 158.27 | −46.0% | 8.37 | 26 Jul 2021 |
| Q4 FY21Jan–Mar 2021 | 1,280.39 | +6.1% | 242.45 | +19.2% | 12.75 | 05 May 2021 |
| Q3 FY21Oct–Dec 2020 | 1,314.33 | +8.7% | 285.62 | +25.7% | 14.88 | 19 Jan 2021 |
| Q2 FY21Jul–Sep 2020 | 1,457.10 | +17.4% | 325.25 | +29.9% | 17.24 | 22 Oct 2020 |
| Q1 FY21Apr–Jun 2020 | 1,341.32 | +41.4% | 293.18 | +145.4% | 15.99 | 23 Jul 2020 |
| Q4 FY20Jan–Mar 2020 | 1,206.83 | +30.2% | 203.45 | +64.5% | 11.92 | 22 May 2020 |
| Q3 FY20Oct–Dec 2019 | 1,209.13 | +18.8% | 227.31 | +34.5% | 12.42 | 22 Jan 2020 |
| Q2 FY20Jul–Sep 2019 | 1,240.87 | +10.1% | 250.45 | +25.2% | 13.06 | 25 Oct 2019 |
| Q1 FY20Apr–Jun 2019 | 948.91 | +10.0% | 119.49 | +32.1% | 6.56 | 30 Jul 2019 |
| Q4 FY19Jan–Mar 2019 | 926.95 | — | 123.70 | — | 6.58 | 09 May 2019 |
| Q3 FY19Oct–Dec 2018 | 1,018.15 | — | 169.06 | — | 9.01 | 22 Jan 2019 |
| Q2 FY19Jul–Sep 2018 | 1,127.06 | — | 200.09 | — | 10.61 | 22 Oct 2018 |
| Q1 FY19Apr–Jun 2018 | 862.53 | — | 90.45 | — | 4.80 | 27 Jul 2018 |
Standalone results
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 1,868.06 | +25.0% | 196.96 | +90.3% | 10.02 | 04 Aug 2026 |
| Q4 FY26Jan–Mar 2026 | 1,718.74 | — | 243.07 | — | 12.37 | 13 Jul 2026 |
| Q3 FY26Oct–Dec 2025 | 1,642.24 | +16.8% | 114.47 | +33.4% | 5.82 | 05 Feb 2026 |
| Q2 FY26Jul–Sep 2025 | 1,796.24 | +13.7% | 179.36 | +8.2% | 9.12 | 04 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 1,494.17 | +1.3% | 103.52 | −41.2% | 5.27 | 05 Aug 2025 |
| Q3 FY25Oct–Dec 2024 | 1,406.09 | −11.5% | 85.81 | −63.2% | 4.37 | 03 Feb 2025 |
| Q2 FY25Jul–Sep 2024 | 1,580.35 | +6.9% | 165.78 | +23.9% | 8.43 | 07 Nov 2024 |
| Q1 FY25Apr–Jun 2024 | 1,475.56 | +10.8% | 176.19 | +80.7% | 8.96 | 14 Aug 2024 |
| Q4 FY24Jan–Mar 2024 | 1,474.55 | +12.8% | 201.87 | +54.6% | 10.27 | 10 May 2024 |
| Q3 FY24Oct–Dec 2023 | 1,588.39 | +21.2% | 233.24 | +95.8% | 11.87 | 06 Feb 2024 |
| Q2 FY24Jul–Sep 2023 | 1,478.84 | +9.2% | 133.84 | −8.6% | 6.81 | 09 Nov 2023 |
| Q1 FY24Apr–Jun 2023 | 1,332.27 | +14.8% | 97.53 | +34.6% | 4.96 | 04 Aug 2023 |
| Q4 FY23Jan–Mar 2023 | 1,307.12 | +0.2% | 130.54 | −48.1% | 6.64 | 06 May 2023 |
| Q3 FY23Oct–Dec 2022 | 1,310.21 | +6.3% | 119.13 | −38.5% | 6.06 | 02 Feb 2023 |
| Q2 FY23Jul–Sep 2022 | 1,354.42 | +13.8% | 146.44 | −6.3% | 7.45 | 11 Nov 2022 |
| Q1 FY23Apr–Jun 2022 | 1,160.33 | −8.6% | 72.46 | −62.4% | 3.69 | 05 Aug 2022 |
| Q4 FY22Jan–Mar 2022 | 1,304.32 | +12.7% | 251.37 | +8.8% | 12.79 | 04 May 2022 |
| Q3 FY22Oct–Dec 2021 | 1,232.83 | −0.2% | 193.58 | −30.2% | 9.85 | 10 Feb 2022 |
| Q2 FY22Jul–Sep 2021 | 1,189.77 | −15.0% | 156.35 | −55.1% | 7.95 | 11 Nov 2021 |
| Q1 FY22Apr–Jun 2021 | 1,269.69 | +0.9% | 192.69 | −39.5% | 9.80 | 26 Jul 2021 |
| Q4 FY21Jan–Mar 2021 | 1,157.24 | +10.4% | 231.11 | −26.5% | 11.76 | 05 May 2021 |
| Q3 FY21Oct–Dec 2020 | 1,235.77 | +17.4% | 277.35 | +20.0% | 14.11 | 19 Jan 2021 |
| Q2 FY21Jul–Sep 2020 | 1,400.01 | +23.4% | 348.30 | +29.6% | 18.02 | 22 Oct 2020 |
| Q1 FY21Apr–Jun 2020 | 1,258.43 | +40.3% | 318.63 | +105.3% | 16.90 | 23 Jul 2020 |
| Q4 FY20Jan–Mar 2020 | 1,048.56 | +23.5% | 314.31 | +191.9% | 16.67 | 22 May 2020 |
| Q3 FY20Oct–Dec 2019 | 1,052.36 | +16.3% | 231.19 | +66.9% | 12.26 | 22 Jan 2020 |
| Q2 FY20Jul–Sep 2019 | 1,134.90 | +3.6% | 268.69 | +7.0% | 14.25 | 25 Oct 2019 |
| Q1 FY20Apr–Jun 2019 | 896.74 | +10.5% | 155.22 | +36.2% | 8.23 | 30 Jul 2019 |
| Q4 FY19Jan–Mar 2019 | 848.70 | — | 107.66 | — | 5.71 | 09 May 2019 |
| Q3 FY19Oct–Dec 2018 | 904.72 | — | 138.51 | — | 7.35 | 22 Jan 2019 |
| Q2 FY19Jul–Sep 2018 | 1,095.43 | — | 251.06 | — | 13.32 | 22 Oct 2018 |
| Q1 FY19Apr–Jun 2018 | 811.42 | — | 113.98 | — | 6.05 | 27 Jul 2018 |
65 filings on record for this company.